◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Alnylam Pharmaceuticals Inc (ALNY)

Name: Alnylam Pharmaceuticals Inc（ALNY）— 財務諸表の推移
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

公式財務諸表に基づく売上高、利益、キャッシュフローの推移。

HEALTHCARE · ウォール街（米国） · 最終更新: 2026-08-16

Alnylam Pharmaceuticals, Inc. discovers, develops, manufactures, and commercializes therapeutics based on ribonucleic acid interference in the United States, Europe, and internationally. The company offers ONPATTRO for hereditary transthyretin-mediated (hATTR) amyloidosis; AMVUTTRA for ATTR and hATTR amyloidosis; Leqvio for hypercholesterolemia; Qfitlia for hemophilia A or B; GIVLAARI for acute hepatic porphyria; and OXLUMO for primary hyperoxaluria type 1.

主要指標

時価総額: $31 billion
売上高（2025-12-31 期末の会計年度）: $3.7B
当期純利益: $314M
売上総利益率: 81.8%
純利益率: 8.5%

インタラクティブチャートと全財務諸表を見る → バリュエーションモデル（DCF）→

年次損益計算書

損益計算書	TTM → 2026-06-30	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31	2020-12-31	2019-12-31	2018-12-31	2017-12-31	2016-12-31	2015-12-31	2014-12-31	2013-12-31	2012-12-31	2011-12-31	2010-12-31	2009-12-31	2008-12-31	2007-12-31	2006-12-31
売上高合計	$4.8B	$3.7B	$2.2B	$1.8B	$1.0B	$844M	$493M	$220M	$75M	$90M	$47M	$41M	$51M	$47M	$67M	$83M	$100M	$101M	$96M	$51M	$27M
売上総利益	$3.8B	$3.0B	$1.9B	$1.5B	$869M	$704M	$415M	$195M	$73M	$90M	$47M	$41M	$51M	$47M	$67M	$83M	$100M	$101M	$96M	$51M	$27M
売上総利益率 %	79.7%	81.8%	85.6%	83.0%	83.7%	83.4%	84.2%	88.6%	97.6%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
営業利益（EBIT）	$1.0B	$502M	($177M)	($282M)	($785M)	($709M)	($828M)	($939M)	($815M)	($500M)	($425M)	($296M)	($405M)	($93M)	($129M)	($55M)	($44M)	($48M)	($28M)	($93M)	($40M)
営業利益率 %	20.8%	13.5%	-7.9%	-15.4%	-75.7%	-83.9%	-168.1%	-427.5%	-1087.6%	-556.2%	-900.3%	-720.3%	-801.0%	-197.0%	-194.0%	-66.2%	-44.0%	-47.9%	-28.9%	-183.1%	-146.7%
当期純利益	$807M	$314M	($278M)	($440M)	($1.1B)	($853M)	($858M)	($886M)	($761M)	($491M)	($410M)	($290M)	($360M)	($89M)	($106M)	($58M)	($44M)	($48M)	($26M)	($85M)	($35M)
純利益率 %	16.8%	8.5%	-12.4%	-24.1%	-109.0%	-101.0%	-174.2%	-403.2%	-1016.6%	-546.0%	-869.6%	-705.8%	-712.8%	-189.2%	-158.9%	-69.7%	-43.5%	-47.3%	-27.3%	-167.9%	-128.5%
EBITDA	—	$631M	($179M)	($258M)	($927M)	($662M)	($736M)	($885M)	($754M)	($487M)	($409M)	($277M)	($172M)	($83M)	($52M)	($50M)	($38M)	($41M)	($19M)	($75M)	($36M)
1株当たり利益（EPS）	$5.90	$2.33	$-2.18	$-3.52	$-9.30	$-7.20	$-7.46	$-8.11	$-7.57	$-5.42	$-4.79	$-3.45	$-4.85	$-1.45	$-2.11	$-1.36	$-1.04	$-1.14	$-0.64	$-2.21	$-1.09
発行済株式数（百万株）	—	135M	128M	125M	122M	118M	115M	109M	101M	91M	86M	84M	74M	62M	50M	42M	42M	42M	41M	39M	32M

出典: 企業の公開資料（SEC）。数値をご利用の前に SEC EDGAR でご確認ください。

貸借対照表、キャッシュフロー計算書、四半期データおよび全財務比率は ALNY のインタラクティブ・ビューアーでご覧いただけます。 /companies/us/ALNY

類似企業

本サイトの情報は教育および情報提供のみを目的としており、投資助言ではありません。目標株価や投資判断は掲載していません。

English version →全銘柄

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.